同和藥業(300636.SZ):預計2024年成熟品種板塊比2023年會有增長,能恢復到與2022年接近的規模
格隆匯1月9日丨同和藥業(300636.SZ)在投資者關係活動上表示,預計2023年收入與去年基本持平,具體數據以審計報吿為準。預計2024年成熟品種板塊比2023年會有增長,能恢復到與2022年接近的規模;CDMO板塊整個行業都不太景氣,預計2024年相對2023年不會有多少增長;內銷板塊2024年還是會保持一定幅度的增長;新品種板塊2024年較樂觀。我們預計2024年四個業務板塊中的三個都有增長,對2024年實現一定幅度的收入增長還是比較有信心。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.